Baicalein attenuates airway inflammation and airway remodeling through inhibition of VEGF and EGFR signaling pathways in an OVA-induced asthma mouse model. This will provide a new basis for the development of baicalein as a treatment for asthma and highlights the potential of network pharmacology and molecular docking in drug discovery and development.
Keyphrases
- molecular docking
- drug discovery
- small cell lung cancer
- signaling pathway
- high glucose
- mouse model
- endothelial cells
- chronic obstructive pulmonary disease
- epidermal growth factor receptor
- diabetic rats
- vascular endothelial growth factor
- tyrosine kinase
- lung function
- molecular dynamics simulations
- drug induced
- pi k akt
- epithelial mesenchymal transition
- allergic rhinitis
- oxidative stress
- type diabetes
- cystic fibrosis
- insulin resistance
- high fat diet induced
- replacement therapy
- smoking cessation